title: [Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone].
abstract: Saquinavir (SQV) is a human immunodeficiency virus (HIV) specific protease inhibitor. When combined with ritonavir (RTV), plasma concentration of SQV is increased. In this study, we examined pharmacokinetics of SQV soft-gel capsule (SQV-SGC) 400 mg twice daily (BID) combined with RTV in HIV-1-infected patients (n = 4) and compared with those of SQV hard-gel capsule (SQV-HGC) 400 mg BID combined with RTV (n = 12). Pharmacokinetics of SQV-SGC 1,200 mg single dose in healthy subjects (n = 10) were also studied. Peak SQV concentration in plasma (Cmax) and area under the plasma concentration-time curve from 0 to 8 hour (AUC0-8 h) of SQV-SGC 400 mg BID combined with RTV group were higher than those of SQV-HGC 400 mg BID combined with RTV group; increase of 14.7% and 25.5%, respectively. Cmax and AUC0-8 h of SQV-SGC were higher than SQV-SGC 1,200 mg single dose group; increase of 3.9 fold and 8.5 fold, respectively. These results indicated that SQV-SGC combined with RTV therapy is the most potent antiviral effect among SQV-SGC with RTV, SQV-HGC with RTV, and SQV-SGC alone.
authors.forename: Kiyoto
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hirabayashi
authors.forename: Kazunari
authors.initials: K
authors.lastname: Imai
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Kikuchi
authors.forename: Natsuo
authors.initials: N
authors.lastname: Tachikawa
authors.forename: Ikumi
authors.initials: I
authors.lastname: Genka
authors.forename: Katsuji
authors.initials: K
authors.lastname: Teruya
authors.forename: Akira
authors.initials: A
authors.lastname: Yasuoka
authors.forename: Shinichi
authors.initials: S
authors.lastname: Oka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kimura
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002214:Capsules; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005782:Gels; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019258:Saquinavir / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D019380:Anti-HIV Agents; D002214:Capsules; D005782:Gels; D017320:HIV Protease Inhibitors; D019258:Saquinavir; D019438:Ritonavir